Evidence map›Paper›PMID 23687126›Full record

ArticleInternational journal of epidemiology2014

Cohort profile: The Japan diabetes complications study: a long-term follow-up of a randomised lifestyle intervention study of type 2 diabetes.

Shiro Tanaka, Sachiko Tanaka, Satoshi Iimuro, Hidetoshi Yamashita, Shigehiro Katayama, Yasuo Ohashi, Yasuo Akanuma, Nobuhiro Yamada, Hirohito Sone, Japan Diabetes Complications Study Group

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of epidemiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Shiro TanakaDepartment of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan, Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan, Department of Ophthalmology, Yamagata University Faculty of Medicine, Yamagata, Japan, Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan, Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan, Department of Internal Medicine, University of Tsukuba Institute of Clinical Medicine, Tsukuba, Ibaraki, Japan and Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Sachiko TanakaDepartment of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan, Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan, Department of Ophthalmology, Yamagata University Faculty of Medicine, Yamagata, Japan, Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan, Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan, Department of Internal Medicine, University of Tsukuba Institute of Clinical Medicine, Tsukuba, Ibaraki, Japan and Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Satoshi IimuroDepartment of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan, Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan, Department of Ophthalmology, Yamagata University Faculty of Medicine, Yamagata, Japan, Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan, Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan, Department of Internal Medicine, University of Tsukuba Institute of Clinical Medicine, Tsukuba, Ibaraki, Japan and Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Hidetoshi YamashitaDepartment of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan, Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan, Department of Ophthalmology, Yamagata University Faculty of Medicine, Yamagata, Japan, Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan, Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan, Department of Internal Medicine, University of Tsukuba Institute of Clinical Medicine, Tsukuba, Ibaraki, Japan and Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Shigehiro KatayamaDepartment of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan, Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan, Department of Ophthalmology, Yamagata University Faculty of Medicine, Yamagata, Japan, Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan, Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan, Department of Internal Medicine, University of Tsukuba Institute of Clinical Medicine, Tsukuba, Ibaraki, Japan and Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Yasuo OhashiDepartment of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan, Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan, Department of Ophthalmology, Yamagata University Faculty of Medicine, Yamagata, Japan, Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan, Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan, Department of Internal Medicine, University of Tsukuba Institute of Clinical Medicine, Tsukuba, Ibaraki, Japan and Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Yasuo AkanumaDepartment of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan, Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan, Department of Ophthalmology, Yamagata University Faculty of Medicine, Yamagata, Japan, Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan, Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan, Department of Internal Medicine, University of Tsukuba Institute of Clinical Medicine, Tsukuba, Ibaraki, Japan and Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Nobuhiro YamadaDepartment of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan, Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan, Department of Ophthalmology, Yamagata University Faculty of Medicine, Yamagata, Japan, Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan, Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan, Department of Internal Medicine, University of Tsukuba Institute of Clinical Medicine, Tsukuba, Ibaraki, Japan and Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
Hirohito SoneDepartment of Clinical Trial Design and Management, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan, Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan, Department of Ophthalmology, Yamagata University Faculty of Medicine, Yamagata, Japan, Department of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan, Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan, Department of Internal Medicine, University of Tsukuba Institute of Clinical Medicine, Tsukuba, Ibaraki, Japan and Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan jdcstudy@md.tsukuba.ac.jp.
Japan Diabetes Complications Study Group
Yamagata University · JPKyoto University Hospital · JPInstitute for Adult Diseases Asahi Life Foundation · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Japan Diabetes Complications Study, a randomised lifestyle intervention study of type 2 diabetes conducted at 59 institutes throughout Japan that enrolled 2033 eligible patients from January 1995 to March 1996, was directed at: (i) determining the incidence and progression rates of complications of diabetes; (ii) exploring clinical risk factors for complications of diabetes; and (iii) determining the association between lifestyle factors, including diet and physical activity, and complications of diabetes, in addition to comparing, in a randomised manner, the effects on type 2 diabetes of an extensive lifestyle intervention and conventional treatment. The protocol for the study originally specified four study populations according to primary outcomes, consisting of: (1) a macroangiopathy group (N = 1771); (ii) a nephropathy group (N = 1607); (iii) a retinopathy-incident group (N = 1221); and (iv) a retinopathy-progression group (N = 410). The primary outcomes were: (i) development of retinopathy; (ii) progression of retinopathy; (iii) development of overt nephropathy; and (iv) occurrence of macroangiopathic events including proven coronary heart disease and stroke. The study was originally planned to follow patients for 8 years, and an extended follow-up is ongoing. Information about primary outcomes, laboratory tests, and other clinical variables for each patient was collected at a central data centre through an annual report from each investigator. Additionally, extensive lifestyle surveys were conducted at baseline and 5 years after the beginning of the study intervention in both the intervention and conventional treatment groups. A description of the occurrence of complications of diabetes and of all-cause mortality, provided in this paper, demonstrated a clear gender-based difference in cardiovascular disease and all-cause mortality.

Indexed as

AgedCohort StudiesDiabetes Mellitus, Type 2Diabetic AngiopathiesDiabetic NephropathiesDiabetic RetinopathyDiet, DiabeticDisease ProgressionExercise TherapyFemaleFollow-Up StudiesHumansJapanLife StyleMaleMiddle AgedCardiovascular diseasedietary surveynephropathyphysical activityretinopathy

Identifiers

PMID23687126
PMCPMC4258763
OpenAlexW2152828875

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.